These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Dermatologic care of bullous pemphigoid]. Delacotte A Soins; 1982 Nov; (393):29-32. PubMed ID: 6760407 [No Abstract] [Full Text] [Related]
27. Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients. Polansky M; Eisenstadt R; DeGrazia T; Zhao X; Liu Y; Feldman R J Am Acad Dermatol; 2019 Jul; 81(1):179-186. PubMed ID: 30923002 [TBL] [Abstract][Full Text] [Related]
28. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Du-Thanh A; Merlet S; Maillard H; Bernard P; Joly P; Estève E; Richard MA; Pauwels C; Ingen-Housz-Oro S; Guillot B; Dereure O Br J Dermatol; 2011 Dec; 165(6):1337-43. PubMed ID: 21777222 [TBL] [Abstract][Full Text] [Related]
29. Complete remission after rituximab therapy in an HIV-positive patient with pemphigus vulgaris. Polansky M; Patel N; Feldman R Br J Dermatol; 2015 Dec; 173(6):1557-9. PubMed ID: 26122850 [No Abstract] [Full Text] [Related]
32. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells. Teraki Y; Hotta T; Shiohara T J Invest Dermatol; 2001 Nov; 117(5):1097-102. PubMed ID: 11710918 [TBL] [Abstract][Full Text] [Related]